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We thank Rhew and colleagues for their letter(1) regarding our recently published article.(2) Their 
concern is that we indicated in our methods that we used an inverse variance weighted method to 
combine summary measures with random-effects models to account for between-study heterogeneity. 
However, in our pooled analysis of the effects of selective serotonin reuptake inhibitors (SSRIs) on 
venous thromboembolism (VTE) risk, we employed a fixed-effect model. Based on their re-analysis 
using a random-effects model, the data suggested that SSRIs may not be associated with an increased 
risk of VTE. Indeed, this is correct. However, this statement does not mean we employed a random-
effects model in every single analysis in our report. Our main analysis employed random-effects 
models in the presence of substantial heterogeneity, but in other subsidiary analyses where 
heterogeneity was low, studies shared one common effect, and in the presence of a limited number of 
studies, we employed fixed-effects models. We should have also indicated this in the methods section. 
Comparing users of antidepressants with non-users (6 studies), we employed a random effects model. 
Heterogeneity was substantial (I2=79%, 53 to 90%; p<0.001). We also used a random-effects model in 
the sensitivity analysis that excluded case-control designs, as heterogeneity was substantial (I2=85%, 
61 to 94%; p<0.001). In subgroup analyses by type of risk estimate reported (hazard ratios vs odds 
ratios), type of VTE (deep vein thrombosis vs pulmonary embolism), gender, and class of 
antidepressants, we utilized fixed-effects models as the number of studies were few and degree of 
heterogeneity ranged from low to moderate. In comparing depression with no depression (3 studies), 
we used a fixed-effects model as heterogeneity was low (I2=0%, 0 to 90%; p=0.44). 
 
In quantifying heterogeneity using the I2, there remains the question of how much is too much 
heterogeneity and when does one apply random-effects models. Higgins and colleagues suggest that 
the categorization of I2 values would not be appropriate for all circumstances, but do tentatively assign 
I2  values of 25%, 50%, and 75% to mean low, moderate, and high heterogeneity respectively.(3) In 
the exploration of variability across studies, the I2 quantification of heterogeneity is just one 
component of this; the most important is the variability in the clinical and methodological aspects. 




several studies will vary according to whether the estimates show the same direction of effect.(3) In 
our analyses of the effects of specific antidepressants on VTE risk, this was based on a subgroup 
analysis. We employed fixed-effects models because of the limited number of studies for each class of 
antidepressant, the degree of heterogeneity ranged from low to high, and the studies shared one 
common effect. The studies were not heterogeneous from a clinical and methodological point of view 
and it was reasonable to assume they shared a common effect, which is a criterion for employing a 
fixed-effect model.(4) Moreover, the majority of the estimates for each study in the subgroup had the 
same direction of effect. The heterogeneity of sample sizes of included studies is another criterion that 
is taken into consideration when deciding to employ a fixed- or random-effects model.(4) When one 
study is larger than one or more smaller studies, a fixed-effects model is preferable.(5) Furthermore, if 
there are few studies available for pooling, a random-effects model will provide poor estimates of the 
width of the distribution of intervention or exposure effects.(6) Given that our data fulfilled these 
criteria, a fixed-effect model was therefore a better approach for this analysis. We would consider an 
I2 of 58.43% to be moderate and not high. Nevertheless, considering the inconsistent effect estimates 
based on random- and fixed-effects models, the association between SSRIs and VTE cannot be 
claimed to be robust. Rhew and colleagues further suggested that based on their re-analysis,(1) the 
inconsistent estimates reported could have broad clinical implications and there may be no concern 
for the therapeutic use of SSRIs related to VTE as an adverse event. In our report, we also estimated 
95% prediction intervals of the pooled estimates of the associations and these contained values below 
1. As we have reported, this implies that although on average there seemed to be evidence of 
associations of depression and antidepressant use with VTE risk, this may not always be so in other 
studies. The associations may be causal or just be due to confounding. We have not proposed any 
guideline recommendations or changes as a result of these findings. The overall evidence is based on 
limited number of studies, characterized by heterogeneity, and deserves further exploration and as we 
have clearly reported, further studies are still warranted to establish the role of depression and 
antidepressant use in VTE development, their potential causative pathways, and if there is a class 
effect of antidepressants on VTE. Furthermore, additional research is needed to ascertain whether it is 
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